PerspectivesCurrent Perspectives of the Use of Sodium–Glucose Transport-2 Inhibitors for Patients With Heart Failure and Chronic Kidney DiseaseVider, Etty PharmD; Sapir, Ravit PharmD; Mosseri, Eli PharmD; Gavioli, Elizabeth PharmD Author Information Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, NY. Correspondence: Etty Vider, BS, PharmD, BCACP, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, 1 University Plaza, Brooklyn, NY 11201 (e-mail: [email protected]). E. Gavioli is a full time employee of Dompe US Inc. The remaining authors report no conflicts of interest. Journal of Cardiovascular Pharmacology: March 2022 - Volume 79 - Issue 3 - p 247-253 doi: 10.1097/FJC.0000000000001176 Buy Metrics Abstract Sodium–glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) are a relatively new class of drugs approved for the treatment of type 2 diabetes. In 2021, the American College of Cardiology recommended the use of SGLT-2 inhibitors in patients with heart failure (HF), with or without type 2 diabetes, because of their morbidity and mortality benefits. The review provides an overview of the efficacy and safety of SGLT-2 inhibitors in HF and chronic kidney disease (CKD). We review the existing literature for SGLT-2 inhibitors by searching PubMed.gov using the keywords SGLT-2 inhibitors, HF, and CKD. A clinical treatment pathway is provided to help guide clinicians in choosing an SGLT-2 inhibitor for their patients with chronic HF and CKD. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.